Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 23, 2025
The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution
Fernando Maluf, Robert L Coleman, Angélica Nogueira-Rodrigues, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
JAMA Network Open
|
May 15, 2025
Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy
Christopher M Tarney, Chunqiao Tian, Leslie M Randall, et al.
Gynecologic Oncology
|
October 27, 2023
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
Leslie M Randall, David M O'Malley, Bradley J Monk, et al.
Molecular Cancer Therapeutics
|
August 28, 2020
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)
Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
NPJ Precision Oncology
|
May 30, 2026
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer
Doris Kim, Heekyung Chung, Mona Abed, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)
Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Lancet (London, England)
|
December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Krishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 23, 2025
The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution
Fernando Maluf, Robert L Coleman, Angélica Nogueira-Rodrigues, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
JAMA Network Open
|
May 15, 2025
Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy
Christopher M Tarney, Chunqiao Tian, Leslie M Randall, et al.
Gynecologic Oncology
|
October 27, 2023
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
Leslie M Randall, David M O'Malley, Bradley J Monk, et al.
Molecular Cancer Therapeutics
|
August 28, 2020
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)
Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
NPJ Precision Oncology
|
May 30, 2026
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer
Doris Kim, Heekyung Chung, Mona Abed, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)
Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Lancet (London, England)
|
December 4, 2023
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2019
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Krishnansu S Tewari, Robert A Burger, Danielle Enserro, et al.
Page
of 6